A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis1
Authors:
- 1 June 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 97 (6) , 1398-1407
Abstract
Balsalazide is a new innovative, mesalamine-containing prodrug that is activated by bacteria in the colon. Balsalazide has been shown previously to be well tolerated and effective in the treatment of acute ulcerative colitis. The aim of this study was to determine the dose-response of balsalazide for efficacy and safety in active, mild-to-moderate ulcerative colitis and to compare this profile with that of mesalamine, pH-dependent, delayed-release tablets. A multicenter, randomized, active control, double-blind, double-dummy, dose-response, parallel-group study was performed comparing balsalazide (6.75 g daily), balsalazide (2.25 g daily), and mesalamine (2.4 g daily), administered for 8 wk to 154 patients with active, mild-to-moderate ulcerative colitis as verified by sigmoidoscopy. Eight weeks of treatment with 6.75 g of balsalazide daily provided significantly greater improvement than did balsalazide (2.25 g daily) in rectal bleeding (64.7% [6.75-g balsalazide] vs 32.4% [2.25-g balsalazide], p < 0.006), stool frequency (58.8% vs 29.4%, p < 0.006), sigmoidoscopic score (78.9% vs 52.5%, p < 0.015), and Physician's Global Assessment (73.7% vs 51.3%, p < 0.03). The efficacy of balsalazide showed a significantly more rapid onset of action than that of mesalamine (2.4 g daily) (2-wk sigmoidocopic score improvement, 54.7% [6.75-g balsalazide] vs 29.4% [2.4-g mesalamine], p = 0.006) with numerically greater improvement at 8 wk in five of seven measured signs and symptoms. Balsalazide (6.75 g daily) was well tolerated, and the safety profile did not differ significantly from that of balsalazide (2.25 g daily) or mesalamine. Eight weeks of treatment with balsalazide (6.75 g daily) is significantly more effective than balsalazide (2.25 g daily) and more rapid in onset than mesalamine (2.4 g daily) in improving signs and symptoms of acute ulcerative colitis. Balsalazide (6.75 g daily) is well tolerated, and the safety profile does not differ from that of balsalazide (2.25 g daily) and mesalamine (2.4 g daily).Keywords
This publication has 17 references indexed in Scilit:
- BalsalazideDrugs, 1998
- Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.Gut, 1997
- Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazineAlimentary Pharmacology & Therapeutics, 1992
- Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel DiseaseDrug Safety, 1991
- Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazineAlimentary Pharmacology & Therapeutics, 1988
- Clinical Tolerance of OlsalazineScandinavian Journal of Gastroenterology, 1988
- Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.BMJ, 1986
- Studies of two novel sulfasalazine analogs, ipsalazide and balsalazideDigestive Diseases and Sciences, 1983
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977
- Absorption, metabolism, and excretion of salicylazosulfapyridine in manClinical Pharmacology & Therapeutics, 1972